BIIB vs HSIC
Biogen vs Henry Schein — AI-powered side-by-side comparison
| Metric | BIIB | HSIC |
|---|
| AI Score |
67
|
65
|
| Price |
$208.02
|
$88.16
|
| P/E Ratio |
36.61×
|
25.47×
|
| ROE |
7.1%
|
12.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
67.7%
|
30.3%
|
| Debt / Equity |
0.44×
|
1.21×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
56.7
|
60.6
|
| Beta |
0.158
|
0.806
|
| Expected Upside |
+5.2%
|
+0.7%
|
AI Committee View
Current Innellis committee reasoning for BIIB versus HSIC.
BIIB leads by 2 points.
BIIB scores 67/100 (Buy) versus HSIC at 65/100 (Buy).
BIIB Committee View
80% agreement
5 analysts
The primary driver is news sentiment is positive (+0.42 across 47 articles, 14d). The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
HSIC Committee View
75% agreement
4 analysts
The primary driver is market regime is bullish (bull market -- normal position sizing). The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth